JP2025516649A - Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物 - Google Patents

Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物 Download PDF

Info

Publication number
JP2025516649A
JP2025516649A JP2024566593A JP2024566593A JP2025516649A JP 2025516649 A JP2025516649 A JP 2025516649A JP 2024566593 A JP2024566593 A JP 2024566593A JP 2024566593 A JP2024566593 A JP 2024566593A JP 2025516649 A JP2025516649 A JP 2025516649A
Authority
JP
Japan
Prior art keywords
compound
atezolizumab
administered
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516649A5 (enExample
Inventor
ジェニファー エン－ウォン，
パブロ サエンス－ロペス ラローチャ，
ジェフリー ラウ，
ニコル ソディル，
ジョアン アイリーン アダムキーウィチ，
ダニーロ マダロ，
マーク アンドリュー マーチャント，
ガウラブ パトゥリア，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2025516649A publication Critical patent/JP2025516649A/ja
Publication of JP2025516649A5 publication Critical patent/JP2025516649A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024566593A 2022-05-12 2023-05-12 Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物 Pending JP2025516649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341361P 2022-05-12 2022-05-12
US63/341,361 2022-05-12
PCT/US2023/066920 WO2023220703A1 (en) 2022-05-12 2023-05-12 Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist

Publications (2)

Publication Number Publication Date
JP2025516649A true JP2025516649A (ja) 2025-05-30
JP2025516649A5 JP2025516649A5 (enExample) 2026-05-20

Family

ID=86710772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566593A Pending JP2025516649A (ja) 2022-05-12 2023-05-12 Ｓｈｐ２阻害剤およびｐｄ－ｌ１結合アンタゴニストを含む方法および組成物

Country Status (10)

Country Link
US (1) US20250312339A1 (enExample)
EP (1) EP4522173A1 (enExample)
JP (1) JP2025516649A (enExample)
KR (1) KR20250012585A (enExample)
CN (1) CN119183377A (enExample)
AR (1) AR129314A1 (enExample)
AU (1) AU2023269154B2 (enExample)
CA (1) CA3248752A1 (enExample)
TW (1) TW202408523A (enExample)
WO (1) WO2023220703A1 (enExample)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
EP3303632B2 (en) 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
US12281118B2 (en) * 2018-11-07 2025-04-22 Shanghai Ringene Biopharma Co., Ltd. Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method, and use
EP4034539A1 (en) * 2019-09-24 2022-08-03 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of making and using the same

Also Published As

Publication number Publication date
KR20250012585A (ko) 2025-01-24
EP4522173A1 (en) 2025-03-19
AU2023269154B2 (en) 2026-05-14
TW202408523A (zh) 2024-03-01
WO2023220703A1 (en) 2023-11-16
AU2023269154A1 (en) 2024-10-10
US20250312339A1 (en) 2025-10-09
CA3248752A1 (en) 2023-11-16
AR129314A1 (es) 2024-08-14
CN119183377A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US12409178B2 (en) Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
JP7749667B2 (ja) 肺がんを治療するためのｋｒａｓｇ１２ｃ阻害剤及びｐｄ－ｌ１結合アンタゴニストを含む方法及び組成物
JP2024529451A (ja) がんを治療するための方法及び組成物
KR20240028452A (ko) 암을 치료하기 위한 방법 및 조성물
US20220193077A1 (en) Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors
AU2023269154B2 (en) Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
US20230090868A1 (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
HK40113732A (en) Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
HK40093627A (en) Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
HK40109234A (en) Methods and compositions for treating cancer
WO2023144973A1 (ja) 抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
EA048671B1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260512